Celaid Therapeutics develops regenerative medicine products using human hematopoietic stem cells sourced from umbilical cord and peripheral blood. The company focuses on creating next-generation cell therapies for blood cancers and genetic disorders by employing a proprietary method for the large-scale amplification of functional stem cells without animal-derived components.
Funding
$6.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cell therapies for blood cancers and genetic disorders face limitations in scalability and often rely on animal-derived components, which can introduce variability and safety concerns. Existing methods for expanding hematopoietic stem cells (HSCs) may not efficiently preserve their functionality, hindering their therapeutic potential.
Solution
Celaid Therapeutics is developing next-generation cell therapies for blood cancers and genetic disorders using human hematopoietic stem cells (HSCs) sourced from umbilical cord and peripheral blood. The company employs a proprietary method for the large-scale amplification of functional HSCs without the use of animal-derived components, ensuring high quality and reducing potential safety risks. This technology aims to provide a more scalable and consistent source of HSCs for cell therapy applications, offering a new treatment option for patients. Celaid's approach focuses on preserving the blood reconstitution capabilities of HSCs during ex vivo expansion.
Target Audience
The primary target audience includes patients with blood cancers and genetic disorders who are candidates for cell therapy, as well as clinicians and researchers in the fields of hematology, oncology, and regenerative medicine.
Features
- Large-scale amplification of functional human HSCs
- Animal-derived component-free culture system
- HSCs sourced from umbilical cord and peripheral blood
- Focus on preserving blood reconstitution capabilities
- Development of cell therapies for blood cancers and genetic disorders